The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Https://www.gov.uk/government/news/new-five-year-plan-to-combat-antimicrobial-resistance
https://www.grandviewresearch.com/industry-analysis/antibiotic-resistance-market
--------------------------
antimicrobial-resistance is a global problem -Opportunity for Coris/LD as they offer AMR detection products -
---- "The Group continues its focus on consolidating the Diagnostics Division post the Launch and Coris acquisitions. After the period end Avacta announced that it is exploring strategic options for the division in a manner which maximises shareholder value "
Anyway David Wilson Avacta Chief Commercial Officer | Driving Global IVD likes this
-----------------------
Department of Health and Social CareDepartment of Health and Social Care
262,695 followers262,695 followers
1h • 1 hour ago
Follow
Today we have launched a new plan to tackle antimicrobial resistance (AMR). This national action plan commits the UK to:
🔵 reduce use of antimicrobials
🔵 strengthen surveillance of drug resistant infections before they emerge
🔵 incentivise industry to develop the next generation of treatments
See our plan on Confronting Antimicrobial Resistance: https://lnkd.in/e9Xj6NxM
hashtag#AMR hashtag#AntimicrobialResistance
UK Research and Innovation, Department for Science, Innovation and Technology, UK Health Security Agency, Department for Environment, Food and Rural Affairs, Cabinet Office"
Good timing
"Launch Diagnostics LimitedLaunch Diagnostics Limited
1,659 followers1,659 followers
1h • Edited • 1 hour ago
On the 4th April 2024 the Medicines and Healthcare products Regulatory Agency (MHRA) approved the combined antibiotic cefepime/enmetazobactam (brand name Exblifep) to treat adult patients with complicated infections of the urinary tract and certain types of pneumonia.
Enmetazobactam blocks the action of beta-lactamases, allowing cefepime to act against bacteria that would otherwise be resistant.
We are pleased to announce the addition of cefepime-enmetazobactam to the Liofilchem MTS (MIC Test Strip) range.
Launch Diagnostics is the exclusive distributor of Liofilchem's portfolio in the UK.
For all your AMR testing solutions, head over to our website: www.launchdiagnostics.com, or contact enquiries@launchdiagnostics.com
#microbiology #antimicrobialstewardship #antimicrobialresistance
#AMR #NHS #antibiotics #antimicrobials #patientcare"
'incentivise industry to develop the next generation of treatments'
OK so Launch is a Distributor of a new product but I wonder if Coris and Avacta DX can benefit.
@ Bella6532 : AMR Global issue not just the UK : Avacta well placed with Coris /LD :
"Anti-Microbial Resistance concern pushed Coris BioConcept to develop a range of assays (RESIST) for rapid detection of antibiotic resistance mechanisms. Aside of this range, another innovative approach for 3GC detection was recently launched with a front line test: BL-RED.
This R&D expertise is ideally suited for “on demand” production of innovative solutions in a rapidly changing world that calls for cutting edge biotechnology to take us forward into a healthy future.
All Coris BioConcept’s products fulfil the CE marking requirements with an ISO 13485 certification and they are used in over 60 countries all over the world.
Coris BioConcept is now part of Avacta Group."
----------------
"Coris BioConcept is a leading expert in the field of rapid diagnostics kits. Based in Belgium and established in 1996, the company develops, produces and markets diagnostic kits, mainly for the detection of human infectious pathogens (bacteria, virus and parasites), and for the detection of antibiotic resistance markers.
These rapid tests are based on the immunochromatographic (also known as lateral flow), the isothermal LAMP and the electrochemical technologies and are extensively used in microbiology laboratories worldwide.
Coris BioConcept is currently involved in multiple collaborative international projects (including Belgian and/or European grants) for the development of new rapid diagnostic assays, with focus on antimicrobial resistance and neglected tropical and emerging diseases.
This R&D expertise is ideally suited for the “on-demand” development or production of innovative solutions in a rapidly changing world that calls for cutting edge biotechnology to take us forward into a healthy future.
All Coris BioConcept’s products fulfill the CE marking requirements and the company is also certified ISO 13485.
--------------
I’ve still never seen anything to validate why Launch was ever bought 🤭😢
"Avacta Diagnostics expected to be overall EBITDA positive in second half of 2024 and cash generative 2025"
Anyway good or bad decision , it happened ,still on Avacta Balance sheet , so worthwhile making it work .
Perhaps Avacta might sell Coris & LD as seperate entities ?
Oops " separate "
Gmcc..gotchya on that...but it says next generation of treatments and I was thinking more on the lines of an Affimer based product...
They’ll never talk above integrating the Affimer into Dx again, now AS has left.